PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study
Author(s) -
Alberto Delaidelli,
Christopher Dunham,
Mariarita Santi,
Gian Luca Negri,
Joanna Triscott,
Olga Zheludkova,
Andrey Golanov,
Marina Ryzhova,
Konstantin Okonechnikov,
Daniel Schrimpf,
Damian Stichel,
David H. Ellison,
Andreas von Deimling,
Marcel Kool,
Stefan M. Pfister,
Vijay Ramaswamy,
Michael D. Taylor,
Andrey Korshunov,
Poul Sorensen
Publication year - 2022
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noac079.587
Subject(s) - medulloblastoma , oncology , medicine , immunohistochemistry , biomarker , multivariate analysis , receiver operating characteristic , biology , bioinformatics , pathology , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom